| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Hypertension | 212 | 2023 | 796 | 35.260 |
Why?
|
| Antihypertensive Agents | 124 | 2023 | 284 | 24.290 |
Why?
|
| Blood Pressure | 121 | 2023 | 646 | 17.690 |
Why?
|
| Hyperaldosteronism | 42 | 2020 | 43 | 9.640 |
Why?
|
| Aldosterone | 38 | 2023 | 66 | 8.080 |
Why?
|
| Drug Resistance | 47 | 2019 | 99 | 7.640 |
Why?
|
| Sleep Apnea, Obstructive | 31 | 2022 | 52 | 7.630 |
Why?
|
| Spironolactone | 19 | 2023 | 39 | 5.560 |
Why?
|
| Blood Pressure Monitoring, Ambulatory | 29 | 2021 | 63 | 4.130 |
Why?
|
| Diuretics | 23 | 2019 | 52 | 3.830 |
Why?
|
| Humans | 284 | 2023 | 37093 | 3.620 |
Why?
|
| Medication Adherence | 12 | 2020 | 179 | 3.570 |
Why?
|
| Blood Pressure Determination | 24 | 2022 | 52 | 2.870 |
Why?
|
| Sympathetic Nervous System | 22 | 2019 | 74 | 2.620 |
Why?
|
| Male | 152 | 2022 | 20025 | 2.420 |
Why?
|
| Middle Aged | 110 | 2023 | 10129 | 2.370 |
Why?
|
| Drug Therapy, Combination | 29 | 2020 | 227 | 2.360 |
Why?
|
| Treatment Failure | 19 | 2020 | 64 | 2.350 |
Why?
|
| Risk Factors | 61 | 2020 | 3562 | 2.330 |
Why?
|
| Female | 154 | 2022 | 20969 | 2.270 |
Why?
|
| Sleep | 6 | 2020 | 152 | 2.270 |
Why?
|
| Granulocyte Colony-Stimulating Factor | 23 | 2002 | 41 | 2.180 |
Why?
|
| Sodium, Dietary | 12 | 2017 | 27 | 2.140 |
Why?
|
| Aged | 82 | 2020 | 6741 | 2.070 |
Why?
|
| Prevalence | 38 | 2020 | 1455 | 2.060 |
Why?
|
| Obesity | 21 | 2021 | 1067 | 2.040 |
Why?
|
| Hydrochlorothiazide | 9 | 2013 | 19 | 1.830 |
Why?
|
| Tetrazoles | 9 | 2013 | 49 | 1.820 |
Why?
|
| Valine | 8 | 2013 | 31 | 1.780 |
Why?
|
| Treatment Outcome | 37 | 2021 | 1369 | 1.730 |
Why?
|
| Stroke | 11 | 2019 | 286 | 1.710 |
Why?
|
| Severity of Illness Index | 18 | 2020 | 610 | 1.660 |
Why?
|
| Cardiovascular Diseases | 21 | 2018 | 664 | 1.630 |
Why?
|
| Prospective Studies | 30 | 2023 | 1378 | 1.610 |
Why?
|
| Coronary Vasospasm | 6 | 2017 | 6 | 1.560 |
Why?
|
| Periodicals as Topic | 5 | 2019 | 49 | 1.540 |
Why?
|
| Practice Guidelines as Topic | 10 | 2020 | 191 | 1.530 |
Why?
|
| Continuous Positive Airway Pressure | 7 | 2022 | 15 | 1.520 |
Why?
|
| Amlodipine | 8 | 2016 | 21 | 1.510 |
Why?
|
| Sodium Chloride, Dietary | 6 | 2021 | 41 | 1.450 |
Why?
|
| Adult | 73 | 2022 | 11712 | 1.380 |
Why?
|
| Hypertension, Malignant | 3 | 2016 | 4 | 1.380 |
Why?
|
| Hypertrophy, Left Ventricular | 8 | 2023 | 45 | 1.370 |
Why?
|
| Adrenalectomy | 6 | 2020 | 25 | 1.340 |
Why?
|
| Disease Management | 5 | 2019 | 61 | 1.290 |
Why?
|
| alpha-Galactosidase | 3 | 2020 | 4 | 1.280 |
Why?
|
| Heart Rate | 23 | 2019 | 253 | 1.270 |
Why?
|
| Ventricular Function, Left | 8 | 2022 | 96 | 1.250 |
Why?
|
| Renin | 15 | 2020 | 30 | 1.220 |
Why?
|
| Prognosis | 17 | 2019 | 739 | 1.200 |
Why?
|
| Risk Assessment | 20 | 2021 | 753 | 1.150 |
Why?
|
| Drug Resistance, Multiple | 3 | 2012 | 27 | 1.150 |
Why?
|
| Coronary Artery Disease | 5 | 2019 | 142 | 1.140 |
Why?
|
| United States | 37 | 2021 | 4223 | 1.120 |
Why?
|
| Renin-Angiotensin System | 9 | 2017 | 36 | 1.060 |
Why?
|
| Renal Insufficiency, Chronic | 6 | 2021 | 169 | 1.040 |
Why?
|
| Circadian Rhythm | 14 | 2020 | 225 | 0.950 |
Why?
|
| Heart Failure | 5 | 2023 | 235 | 0.930 |
Why?
|
| Intensive Care Units, Neonatal | 6 | 2017 | 42 | 0.930 |
Why?
|
| Sodium Chloride Symporter Inhibitors | 4 | 2019 | 7 | 0.920 |
Why?
|
| Heart Ventricles | 4 | 2022 | 110 | 0.890 |
Why?
|
| Sodium | 12 | 2019 | 103 | 0.890 |
Why?
|
| Chlorthalidone | 5 | 2017 | 6 | 0.880 |
Why?
|
| Ambulatory Care | 3 | 2019 | 75 | 0.870 |
Why?
|
| Follow-Up Studies | 14 | 2019 | 974 | 0.870 |
Why?
|
| Retrospective Studies | 16 | 2022 | 2026 | 0.860 |
Why?
|
| Denervation | 3 | 2016 | 27 | 0.860 |
Why?
|
| Population Surveillance | 2 | 2014 | 238 | 0.840 |
Why?
|
| Diastole | 9 | 2023 | 42 | 0.800 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 8 | 2022 | 69 | 0.790 |
Why?
|
| Infant, Newborn | 25 | 2017 | 894 | 0.790 |
Why?
|
| Recombinant Proteins | 16 | 2020 | 515 | 0.790 |
Why?
|
| Infant, Premature, Diseases | 5 | 2013 | 64 | 0.790 |
Why?
|
| Double-Blind Method | 19 | 2021 | 286 | 0.780 |
Why?
|
| Kidney Diseases | 5 | 2011 | 167 | 0.780 |
Why?
|
| Receptors, Mineralocorticoid | 3 | 2018 | 11 | 0.780 |
Why?
|
| Neutropenia | 6 | 2002 | 18 | 0.770 |
Why?
|
| Kidney | 9 | 2017 | 337 | 0.770 |
Why?
|
| Reserpine | 1 | 2020 | 2 | 0.750 |
Why?
|
| Fabry Disease | 1 | 2020 | 2 | 0.750 |
Why?
|
| Comorbidity | 12 | 2016 | 623 | 0.740 |
Why?
|
| Endothelium, Vascular | 10 | 2021 | 237 | 0.740 |
Why?
|
| Life Style | 10 | 2020 | 308 | 0.740 |
Why?
|
| Cardiac Volume | 2 | 2018 | 4 | 0.740 |
Why?
|
| Mutagenesis | 1 | 2020 | 89 | 0.730 |
Why?
|
| Amino Acid Substitution | 1 | 2020 | 132 | 0.720 |
Why?
|
| Wakefulness | 1 | 2020 | 21 | 0.720 |
Why?
|
| Weight Loss | 5 | 2015 | 131 | 0.720 |
Why?
|
| Forearm | 2 | 2019 | 8 | 0.710 |
Why?
|
| Sleep Apnea Syndromes | 6 | 2019 | 29 | 0.710 |
Why?
|
| Protein Multimerization | 1 | 2020 | 103 | 0.690 |
Why?
|
| Metanephrine | 1 | 2019 | 1 | 0.670 |
Why?
|
| Receptors, Granulocyte Colony-Stimulating Factor | 7 | 2001 | 8 | 0.670 |
Why?
|
| Catecholamines | 2 | 2019 | 44 | 0.660 |
Why?
|
| Arm | 1 | 2019 | 28 | 0.660 |
Why?
|
| Time Factors | 14 | 2020 | 1742 | 0.650 |
Why?
|
| Aortic Valve Insufficiency | 1 | 2018 | 3 | 0.640 |
Why?
|
| Health Promotion | 2 | 2015 | 653 | 0.640 |
Why?
|
| Heart Valve Prosthesis Implantation | 1 | 2018 | 19 | 0.640 |
Why?
|
| Mitral Valve Insufficiency | 1 | 2018 | 13 | 0.630 |
Why?
|
| Primary Health Care | 2 | 2013 | 294 | 0.630 |
Why?
|
| Coronary Artery Bypass | 1 | 2018 | 43 | 0.620 |
Why?
|
| Diabetes Mellitus, Type 2 | 3 | 2014 | 643 | 0.620 |
Why?
|
| Fetal Macrosomia | 1 | 2017 | 12 | 0.610 |
Why?
|
| Birth Weight | 2 | 2017 | 90 | 0.610 |
Why?
|
| 11-beta-Hydroxysteroid Dehydrogenase Type 2 | 1 | 2017 | 3 | 0.600 |
Why?
|
| Diagnostic Errors | 2 | 2017 | 20 | 0.590 |
Why?
|
| Cardiovascular System | 1 | 2017 | 33 | 0.580 |
Why?
|
| Atrial Fibrillation | 1 | 2018 | 101 | 0.570 |
Why?
|
| Coronary Disease | 2 | 2016 | 124 | 0.570 |
Why?
|
| Sleep Deprivation | 1 | 2016 | 26 | 0.560 |
Why?
|
| Infant, Premature | 10 | 2001 | 129 | 0.560 |
Why?
|
| Sleep Initiation and Maintenance Disorders | 1 | 2016 | 63 | 0.540 |
Why?
|
| American Heart Association | 6 | 2021 | 21 | 0.540 |
Why?
|
| Cross-Sectional Studies | 10 | 2021 | 2721 | 0.520 |
Why?
|
| Aged, 80 and over | 15 | 2020 | 2379 | 0.510 |
Why?
|
| Incidence | 11 | 2019 | 922 | 0.510 |
Why?
|
| Aging | 4 | 2015 | 664 | 0.500 |
Why?
|
| Awards and Prizes | 1 | 2015 | 29 | 0.500 |
Why?
|
| Diet, Sodium-Restricted | 3 | 2015 | 11 | 0.500 |
Why?
|
| Obstetric Labor, Premature | 3 | 2001 | 13 | 0.490 |
Why?
|
| Polysomnography | 7 | 2022 | 42 | 0.490 |
Why?
|
| Occupational Health Services | 1 | 2014 | 8 | 0.490 |
Why?
|
| Leadership | 1 | 2015 | 76 | 0.490 |
Why?
|
| Clinical Trials as Topic | 6 | 2016 | 204 | 0.480 |
Why?
|
| Fetus | 6 | 2000 | 105 | 0.470 |
Why?
|
| Granulocyte-Macrophage Colony-Stimulating Factor | 5 | 2001 | 19 | 0.470 |
Why?
|
| Sex Factors | 10 | 2019 | 898 | 0.470 |
Why?
|
| Age Factors | 9 | 2019 | 1033 | 0.470 |
Why?
|
| Bartter Syndrome | 1 | 2013 | 1 | 0.460 |
Why?
|
| Demography | 2 | 2014 | 175 | 0.460 |
Why?
|
| Ventricular Remodeling | 4 | 2023 | 57 | 0.460 |
Why?
|
| Patient Participation | 1 | 2014 | 75 | 0.460 |
Why?
|
| Uric Acid | 5 | 2021 | 26 | 0.460 |
Why?
|
| Myocardial Infarction | 4 | 2014 | 225 | 0.450 |
Why?
|
| Placenta | 5 | 2001 | 97 | 0.440 |
Why?
|
| Albuminuria | 5 | 2021 | 76 | 0.440 |
Why?
|
| Glomerular Filtration Rate | 5 | 2021 | 139 | 0.420 |
Why?
|
| Mutation | 3 | 2016 | 1095 | 0.420 |
Why?
|
| Hypotension, Orthostatic | 1 | 2012 | 5 | 0.410 |
Why?
|
| Water-Electrolyte Imbalance | 1 | 2011 | 2 | 0.410 |
Why?
|
| Pregnancy | 17 | 2017 | 1549 | 0.400 |
Why?
|
| Sodium Channel Blockers | 1 | 2011 | 17 | 0.400 |
Why?
|
| Renal Artery Obstruction | 5 | 2009 | 6 | 0.400 |
Why?
|
| Myocardial Contraction | 3 | 2022 | 48 | 0.390 |
Why?
|
| Vasodilation | 4 | 2015 | 65 | 0.390 |
Why?
|
| Kidney Failure, Chronic | 4 | 2015 | 233 | 0.380 |
Why?
|
| Xanthine Oxidase | 2 | 2022 | 8 | 0.380 |
Why?
|
| Enalaprilat | 2 | 2001 | 2 | 0.380 |
Why?
|
| Adrenal Gland Neoplasms | 4 | 2020 | 17 | 0.370 |
Why?
|
| Animals | 25 | 2019 | 15081 | 0.370 |
Why?
|
| Predictive Value of Tests | 8 | 2023 | 400 | 0.370 |
Why?
|
| Heart Atria | 3 | 2023 | 26 | 0.370 |
Why?
|
| Alabama | 5 | 2015 | 51 | 0.370 |
Why?
|
| Eosinophilia | 2 | 2000 | 18 | 0.370 |
Why?
|
| Weight Gain | 2 | 2017 | 136 | 0.370 |
Why?
|
| Pheochromocytoma | 3 | 2020 | 11 | 0.360 |
Why?
|
| Case-Control Studies | 11 | 2019 | 1130 | 0.360 |
Why?
|
| Potassium | 6 | 2020 | 112 | 0.360 |
Why?
|
| Enzyme Inhibitors | 2 | 2011 | 433 | 0.350 |
Why?
|
| Milk, Human | 2 | 2000 | 33 | 0.350 |
Why?
|
| Allopurinol | 2 | 2021 | 12 | 0.340 |
Why?
|
| Consensus | 2 | 2019 | 45 | 0.340 |
Why?
|
| Reflex | 4 | 2001 | 34 | 0.330 |
Why?
|
| Gestational Age | 9 | 2017 | 190 | 0.330 |
Why?
|
| Societies, Medical | 3 | 2019 | 66 | 0.330 |
Why?
|
| Adolescent | 15 | 2021 | 5363 | 0.330 |
Why?
|
| Amiloride | 3 | 2018 | 18 | 0.330 |
Why?
|
| Body Mass Index | 7 | 2019 | 854 | 0.320 |
Why?
|
| Fetal Blood | 5 | 2001 | 50 | 0.320 |
Why?
|
| Calcium Channel Blockers | 5 | 2007 | 56 | 0.320 |
Why?
|
| Sympathectomy | 3 | 2016 | 7 | 0.310 |
Why?
|
| Hydrocortisone | 3 | 2017 | 78 | 0.310 |
Why?
|
| DNA, Mitochondrial | 3 | 2022 | 175 | 0.310 |
Why?
|
| Dose-Response Relationship, Drug | 8 | 2014 | 1039 | 0.310 |
Why?
|
| Drug Combinations | 5 | 2009 | 98 | 0.310 |
Why?
|
| Proteinuria | 1 | 2007 | 50 | 0.310 |
Why?
|
| Magnetic Resonance Imaging, Cine | 3 | 2018 | 38 | 0.300 |
Why?
|
| Electrocardiography | 3 | 2018 | 156 | 0.300 |
Why?
|
| Terminology as Topic | 2 | 2019 | 34 | 0.300 |
Why?
|
| Randomized Controlled Trials as Topic | 5 | 2016 | 268 | 0.300 |
Why?
|
| Hyperkalemia | 3 | 2012 | 15 | 0.300 |
Why?
|
| Hospitals, University | 2 | 2019 | 38 | 0.300 |
Why?
|
| Phenotype | 4 | 2019 | 689 | 0.300 |
Why?
|
| Creatinine | 4 | 2013 | 103 | 0.300 |
Why?
|
| Delivery of Health Care, Integrated | 2 | 2020 | 26 | 0.300 |
Why?
|
| Neutrophils | 9 | 2001 | 131 | 0.290 |
Why?
|
| Erythropoiesis | 2 | 1996 | 13 | 0.290 |
Why?
|
| Recurrence | 1 | 2007 | 131 | 0.280 |
Why?
|
| Patient Compliance | 5 | 2014 | 212 | 0.280 |
Why?
|
| Myocardial Ischemia | 3 | 2016 | 75 | 0.280 |
Why?
|
| Bacterial Infections | 2 | 1997 | 43 | 0.280 |
Why?
|
| Disease Outbreaks | 1 | 2007 | 155 | 0.270 |
Why?
|
| Exercise | 5 | 2020 | 613 | 0.270 |
Why?
|
| Survival Rate | 6 | 2015 | 311 | 0.270 |
Why?
|
| Hypokalemia | 3 | 2012 | 11 | 0.270 |
Why?
|
| Stroke Volume | 3 | 2012 | 89 | 0.270 |
Why?
|
| Leukocyte Count | 8 | 2001 | 77 | 0.260 |
Why?
|
| Systole | 5 | 2020 | 61 | 0.260 |
Why?
|
| Sodium Chloride | 3 | 1995 | 55 | 0.250 |
Why?
|
| Magnetic Resonance Imaging | 6 | 2022 | 481 | 0.250 |
Why?
|
| Atrial Natriuretic Factor | 3 | 2008 | 12 | 0.250 |
Why?
|
| Hemorheology | 1 | 2004 | 8 | 0.240 |
Why?
|
| Chorioamnionitis | 2 | 2001 | 6 | 0.240 |
Why?
|
| Staphylococcus | 1 | 2004 | 9 | 0.240 |
Why?
|
| Urease | 1 | 2004 | 15 | 0.240 |
Why?
|
| Drug Chronotherapy | 2 | 2015 | 2 | 0.230 |
Why?
|
| Cold Temperature | 4 | 2000 | 40 | 0.230 |
Why?
|
| Kidney Function Tests | 2 | 2015 | 29 | 0.230 |
Why?
|
| Cohort Studies | 4 | 2019 | 1492 | 0.230 |
Why?
|
| Ventricular Dysfunction, Left | 2 | 2014 | 85 | 0.220 |
Why?
|
| Brachial Artery | 4 | 2015 | 28 | 0.220 |
Why?
|
| Young Adult | 11 | 2021 | 4268 | 0.220 |
Why?
|
| Cross-Over Studies | 5 | 2021 | 108 | 0.220 |
Why?
|
| Nicardipine | 2 | 2001 | 10 | 0.220 |
Why?
|
| Rats, Inbred SHR | 8 | 2001 | 32 | 0.220 |
Why?
|
| Defibrillators, Implantable | 2 | 2018 | 35 | 0.220 |
Why?
|
| Rats, Inbred WKY | 8 | 1999 | 23 | 0.210 |
Why?
|
| Reference Values | 5 | 2010 | 212 | 0.210 |
Why?
|
| Renal Circulation | 1 | 2002 | 21 | 0.210 |
Why?
|
| Water-Electrolyte Balance | 2 | 2019 | 17 | 0.210 |
Why?
|
| Norepinephrine | 2 | 2001 | 110 | 0.210 |
Why?
|
| Sex Distribution | 3 | 2017 | 215 | 0.200 |
Why?
|
| Respiratory Distress Syndrome, Newborn | 2 | 2017 | 18 | 0.200 |
Why?
|
| Diet | 5 | 2019 | 801 | 0.200 |
Why?
|
| Uricosuric Agents | 1 | 2021 | 1 | 0.200 |
Why?
|
| Granulocytes | 3 | 2000 | 29 | 0.200 |
Why?
|
| Autoimmune Diseases | 1 | 2002 | 57 | 0.200 |
Why?
|
| Diagnosis, Differential | 3 | 2020 | 217 | 0.200 |
Why?
|
| Drug Administration Schedule | 5 | 2014 | 143 | 0.200 |
Why?
|
| Natriuretic Peptide, Brain | 3 | 2013 | 17 | 0.200 |
Why?
|
| Analysis of Variance | 3 | 2019 | 550 | 0.190 |
Why?
|
| Sympatholytics | 2 | 2019 | 14 | 0.190 |
Why?
|
| Drug Interactions | 3 | 2009 | 141 | 0.190 |
Why?
|
| Kidney Transplantation | 1 | 2002 | 86 | 0.190 |
Why?
|
| Lamivudine | 1 | 2000 | 20 | 0.190 |
Why?
|
| Hematology | 1 | 2000 | 3 | 0.190 |
Why?
|
| Neonatology | 1 | 2000 | 7 | 0.190 |
Why?
|
| Intestines | 2 | 2000 | 64 | 0.190 |
Why?
|
| Lisinopril | 3 | 2016 | 4 | 0.190 |
Why?
|
| RNA, Messenger | 7 | 2001 | 1207 | 0.190 |
Why?
|
| Enzyme Stability | 1 | 2020 | 35 | 0.190 |
Why?
|
| Hematologic Diseases | 1 | 2000 | 14 | 0.190 |
Why?
|
| Epinephrine | 1 | 2020 | 36 | 0.190 |
Why?
|
| Electric Stimulation Therapy | 2 | 2018 | 9 | 0.180 |
Why?
|
| Adrenal Glands | 1 | 2020 | 19 | 0.180 |
Why?
|
| Interleukin-5 | 1 | 2000 | 7 | 0.180 |
Why?
|
| Hemodynamics | 2 | 2018 | 91 | 0.180 |
Why?
|
| Drug Delivery Systems | 1 | 2002 | 202 | 0.180 |
Why?
|
| Losartan | 3 | 2008 | 32 | 0.180 |
Why?
|
| Glycosylation | 1 | 2020 | 100 | 0.180 |
Why?
|
| Intensive Care Units | 1 | 2000 | 59 | 0.180 |
Why?
|
| Sphygmomanometers | 1 | 2020 | 1 | 0.180 |
Why?
|
| Catalytic Domain | 1 | 2020 | 109 | 0.180 |
Why?
|
| Mutation, Missense | 1 | 2020 | 83 | 0.180 |
Why?
|
| Hematopoietic Stem Cells | 2 | 1996 | 43 | 0.180 |
Why?
|
| Angiotensin II Type 1 Receptor Blockers | 2 | 2011 | 37 | 0.180 |
Why?
|
| Hot Temperature | 1 | 2020 | 128 | 0.180 |
Why?
|
| Multivariate Analysis | 5 | 2015 | 583 | 0.170 |
Why?
|
| Chromatography, Liquid | 1 | 2020 | 142 | 0.170 |
Why?
|
| Myocardium | 1 | 2001 | 235 | 0.170 |
Why?
|
| Contraceptives, Oral | 2 | 2007 | 14 | 0.170 |
Why?
|
| Hypernatremia | 1 | 2019 | 10 | 0.170 |
Why?
|
| Postoperative Complications | 1 | 2020 | 210 | 0.170 |
Why?
|
| Bone Marrow | 5 | 2000 | 37 | 0.170 |
Why?
|
| Rats | 11 | 2001 | 3483 | 0.160 |
Why?
|
| Pilot Projects | 4 | 2016 | 661 | 0.160 |
Why?
|
| Tandem Mass Spectrometry | 1 | 2020 | 182 | 0.160 |
Why?
|
| Baroreflex | 2 | 2012 | 11 | 0.160 |
Why?
|
| Sodium Channels | 2 | 2014 | 67 | 0.160 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 4 | 2000 | 448 | 0.160 |
Why?
|
| Postoperative Period | 1 | 2018 | 27 | 0.160 |
Why?
|
| Hypoglossal Nerve | 1 | 2018 | 10 | 0.160 |
Why?
|
| Mitral Valve | 1 | 2018 | 19 | 0.160 |
Why?
|
| Alcohol Drinking | 4 | 2019 | 519 | 0.160 |
Why?
|
| Diseases in Twins | 2 | 1998 | 6 | 0.160 |
Why?
|
| Aortic Valve | 1 | 2018 | 23 | 0.160 |
Why?
|
| Sympathomimetics | 1 | 2017 | 8 | 0.160 |
Why?
|
| Pharmacogenetics | 2 | 2008 | 49 | 0.160 |
Why?
|
| Pressoreceptors | 3 | 1994 | 6 | 0.160 |
Why?
|
| Chronic Disease | 3 | 2011 | 484 | 0.150 |
Why?
|
| Accidental Falls | 1 | 2018 | 26 | 0.150 |
Why?
|
| DNA Copy Number Variations | 1 | 2017 | 28 | 0.150 |
Why?
|
| Nutrition Surveys | 3 | 2019 | 242 | 0.150 |
Why?
|
| Birth Injuries | 1 | 2017 | 9 | 0.150 |
Why?
|
| Hospitals, Teaching | 1 | 2017 | 27 | 0.150 |
Why?
|
| Hypoglycemia | 1 | 2017 | 17 | 0.150 |
Why?
|
| Gene Dosage | 1 | 2017 | 75 | 0.150 |
Why?
|
| Cortisone | 1 | 2017 | 3 | 0.150 |
Why?
|
| Patient Admission | 1 | 2017 | 41 | 0.150 |
Why?
|
| Cesarean Section | 1 | 2017 | 55 | 0.150 |
Why?
|
| Logistic Models | 4 | 2014 | 923 | 0.150 |
Why?
|
| Hematopoiesis, Extramedullary | 1 | 1996 | 1 | 0.150 |
Why?
|
| Spleen | 2 | 1996 | 199 | 0.150 |
Why?
|
| Drug Therapy | 2 | 2011 | 17 | 0.150 |
Why?
|
| Chi-Square Distribution | 3 | 2015 | 225 | 0.140 |
Why?
|
| Diabetes, Gestational | 1 | 2017 | 47 | 0.140 |
Why?
|
| Diabetes Mellitus | 4 | 2015 | 485 | 0.140 |
Why?
|
| Leukemoid Reaction | 1 | 1996 | 1 | 0.140 |
Why?
|
| Health Behavior | 2 | 2019 | 537 | 0.140 |
Why?
|
| Mass Screening | 2 | 2014 | 462 | 0.140 |
Why?
|
| Gout Suppressants | 1 | 2016 | 5 | 0.140 |
Why?
|
| Publishing | 1 | 2017 | 24 | 0.140 |
Why?
|
| Hyperuricemia | 1 | 2016 | 10 | 0.140 |
Why?
|
| Chytridiomycota | 1 | 2016 | 3 | 0.140 |
Why?
|
| Cause of Death | 2 | 2014 | 156 | 0.140 |
Why?
|
| Animal Diseases | 1 | 2016 | 5 | 0.140 |
Why?
|
| Amphibians | 1 | 2016 | 10 | 0.140 |
Why?
|
| Blood Pressure Monitors | 1 | 2016 | 1 | 0.140 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2020 | 404 | 0.140 |
Why?
|
| Women's Health | 1 | 1997 | 145 | 0.140 |
Why?
|
| Polymerase Chain Reaction | 6 | 2001 | 448 | 0.140 |
Why?
|
| Solitary Nucleus | 1 | 1996 | 5 | 0.140 |
Why?
|
| Femoral Artery | 1 | 1996 | 12 | 0.140 |
Why?
|
| Mycoses | 1 | 2016 | 30 | 0.140 |
Why?
|
| Editorial Policies | 1 | 2016 | 13 | 0.130 |
Why?
|
| Polymorphism, Genetic | 2 | 2011 | 191 | 0.130 |
Why?
|
| Valerates | 1 | 2015 | 2 | 0.130 |
Why?
|
| Geography | 2 | 2013 | 96 | 0.130 |
Why?
|
| Infant, Newborn, Diseases | 1 | 1995 | 21 | 0.130 |
Why?
|
| Virus Diseases | 1 | 1995 | 22 | 0.130 |
Why?
|
| Normetanephrine | 1 | 2015 | 3 | 0.130 |
Why?
|
| Cardiography, Impedance | 1 | 2015 | 5 | 0.130 |
Why?
|
| Glutamine | 1 | 2015 | 40 | 0.130 |
Why?
|
| Positive-Pressure Respiration | 1 | 2015 | 3 | 0.130 |
Why?
|
| Bone Marrow Cells | 5 | 1998 | 81 | 0.130 |
Why?
|
| Competitive Behavior | 1 | 2015 | 13 | 0.130 |
Why?
|
| Haplotypes | 1 | 2016 | 182 | 0.130 |
Why?
|
| Industrial Microbiology | 1 | 2015 | 5 | 0.130 |
Why?
|
| Pichia | 1 | 2015 | 10 | 0.130 |
Why?
|
| Vascular Resistance | 1 | 2015 | 34 | 0.130 |
Why?
|
| Inflammation Mediators | 1 | 2016 | 123 | 0.130 |
Why?
|
| Ischemic Attack, Transient | 1 | 2015 | 20 | 0.130 |
Why?
|
| Dietary Supplements | 2 | 2015 | 208 | 0.130 |
Why?
|
| Arginine | 1 | 2015 | 73 | 0.130 |
Why?
|
| COS Cells | 1 | 2015 | 69 | 0.130 |
Why?
|
| Ecosystem | 1 | 2016 | 123 | 0.130 |
Why?
|
| Proportional Hazards Models | 5 | 2016 | 441 | 0.130 |
Why?
|
| Regression Analysis | 3 | 2011 | 455 | 0.130 |
Why?
|
| Receptors, Glucagon | 1 | 2014 | 2 | 0.120 |
Why?
|
| Glucagon-Like Peptides | 1 | 2014 | 3 | 0.120 |
Why?
|
| Immunoglobulin Fc Fragments | 1 | 2014 | 5 | 0.120 |
Why?
|
| Energy Metabolism | 1 | 2016 | 168 | 0.120 |
Why?
|
| Waist Circumference | 2 | 2013 | 89 | 0.120 |
Why?
|
| Cognition | 2 | 2015 | 398 | 0.120 |
Why?
|
| Physicians | 1 | 2016 | 163 | 0.120 |
Why?
|
| Erythropoietin | 3 | 2000 | 39 | 0.120 |
Why?
|
| Carbolines | 1 | 2013 | 15 | 0.120 |
Why?
|
| Infant, Low Birth Weight | 2 | 2007 | 39 | 0.120 |
Why?
|
| Protein Structure, Tertiary | 1 | 2015 | 408 | 0.120 |
Why?
|
| Nephrocalcinosis | 1 | 2013 | 1 | 0.120 |
Why?
|
| Single-Blind Method | 2 | 2013 | 55 | 0.110 |
Why?
|
| Indomethacin | 1 | 2013 | 28 | 0.110 |
Why?
|
| Socioeconomic Factors | 2 | 2019 | 1067 | 0.110 |
Why?
|
| DNA Damage | 1 | 2016 | 352 | 0.110 |
Why?
|
| Recombinant Fusion Proteins | 1 | 2014 | 295 | 0.110 |
Why?
|
| Immunoglobulins, Intravenous | 3 | 2002 | 19 | 0.110 |
Why?
|
| C-Reactive Protein | 3 | 2021 | 149 | 0.110 |
Why?
|
| Longitudinal Studies | 4 | 2019 | 885 | 0.110 |
Why?
|
| Congresses as Topic | 2 | 2014 | 42 | 0.110 |
Why?
|
| Colony-Forming Units Assay | 3 | 1996 | 12 | 0.110 |
Why?
|
| Self Care | 1 | 2014 | 159 | 0.110 |
Why?
|
| Population Groups | 1 | 2013 | 56 | 0.110 |
Why?
|
| Liver | 5 | 2000 | 479 | 0.110 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2013 | 121 | 0.110 |
Why?
|
| Disease Progression | 1 | 2015 | 601 | 0.110 |
Why?
|
| Stress, Physiological | 1 | 1993 | 150 | 0.110 |
Why?
|
| Reproducibility of Results | 3 | 2021 | 935 | 0.110 |
Why?
|
| Muscle, Skeletal | 1 | 1994 | 282 | 0.110 |
Why?
|
| Risk | 2 | 2010 | 267 | 0.100 |
Why?
|
| Vitamin D | 1 | 2014 | 196 | 0.100 |
Why?
|
| Amino Acid Sequence | 1 | 2015 | 1180 | 0.100 |
Why?
|
| Kidney Medulla | 1 | 2011 | 6 | 0.100 |
Why?
|
| Feasibility Studies | 3 | 2018 | 208 | 0.100 |
Why?
|
| Ethanolamines | 1 | 2011 | 12 | 0.100 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2014 | 222 | 0.100 |
Why?
|
| Benzopyrans | 1 | 2011 | 14 | 0.100 |
Why?
|
| Placebos | 1 | 2011 | 37 | 0.100 |
Why?
|
| Adrenocorticotropic Hormone | 1 | 2011 | 24 | 0.100 |
Why?
|
| Age of Onset | 2 | 2010 | 100 | 0.100 |
Why?
|
| Molecular Sequence Data | 1 | 2015 | 1568 | 0.100 |
Why?
|
| Community Health Services | 1 | 2013 | 185 | 0.100 |
Why?
|
| Sexual Dysfunction, Physiological | 1 | 2011 | 14 | 0.100 |
Why?
|
| Airway Resistance | 1 | 2011 | 7 | 0.100 |
Why?
|
| Hormones | 1 | 2011 | 55 | 0.100 |
Why?
|
| Universities | 1 | 2015 | 442 | 0.100 |
Why?
|
| Angiotensinogen | 1 | 2011 | 5 | 0.100 |
Why?
|
| Amniotic Fluid | 2 | 2001 | 15 | 0.100 |
Why?
|
| Motivation | 1 | 2015 | 436 | 0.100 |
Why?
|
| Dementia | 1 | 2012 | 131 | 0.100 |
Why?
|
| Anthropometry | 1 | 2011 | 97 | 0.100 |
Why?
|
| Bronchoalveolar Lavage Fluid | 2 | 2001 | 56 | 0.100 |
Why?
|
| Peptidyl-Dipeptidase A | 1 | 2011 | 31 | 0.100 |
Why?
|
| Biomedical Research | 1 | 2016 | 400 | 0.100 |
Why?
|
| Evidence-Based Medicine | 1 | 2011 | 97 | 0.100 |
Why?
|
| Sensitivity and Specificity | 3 | 2016 | 562 | 0.100 |
Why?
|
| Kinetics | 2 | 2004 | 708 | 0.100 |
Why?
|
| Infusions, Intravenous | 1 | 2010 | 47 | 0.090 |
Why?
|
| Salts | 1 | 2010 | 16 | 0.090 |
Why?
|
| Nitric Oxide Synthase Type III | 1 | 2011 | 67 | 0.090 |
Why?
|
| Genetic Loci | 1 | 2011 | 90 | 0.090 |
Why?
|
| Chronobiology Disorders | 1 | 2010 | 3 | 0.090 |
Why?
|
| Eosinophils | 2 | 2000 | 20 | 0.090 |
Why?
|
| Body Weight | 4 | 1997 | 434 | 0.090 |
Why?
|
| Immunohistochemistry | 4 | 2000 | 893 | 0.090 |
Why?
|
| Cognition Disorders | 1 | 2012 | 233 | 0.090 |
Why?
|
| Cardiomegaly | 1 | 2010 | 41 | 0.090 |
Why?
|
| Smoking | 5 | 2019 | 940 | 0.090 |
Why?
|
| Pituitary ACTH Hypersecretion | 1 | 2009 | 2 | 0.090 |
Why?
|
| Endothelial Cells | 1 | 2013 | 308 | 0.090 |
Why?
|
| Adipocytes | 1 | 2010 | 58 | 0.090 |
Why?
|
| Thrombopoietin | 2 | 1999 | 4 | 0.080 |
Why?
|
| Cardiovascular Agents | 1 | 2009 | 20 | 0.080 |
Why?
|
| Image Interpretation, Computer-Assisted | 1 | 2009 | 61 | 0.080 |
Why?
|
| Organ Specificity | 2 | 1999 | 129 | 0.080 |
Why?
|
| Ultrasonography | 2 | 2011 | 112 | 0.080 |
Why?
|
| Spain | 2 | 2019 | 36 | 0.080 |
Why?
|
| Dyslipidemias | 1 | 2009 | 43 | 0.080 |
Why?
|
| Up-Regulation | 1 | 2011 | 513 | 0.080 |
Why?
|
| Heart | 1 | 2010 | 180 | 0.080 |
Why?
|
| Natriuresis | 1 | 2007 | 11 | 0.080 |
Why?
|
| Depression | 1 | 2014 | 712 | 0.080 |
Why?
|
| Angiotensin II | 2 | 2012 | 97 | 0.080 |
Why?
|
| Vasodilator Agents | 3 | 2014 | 56 | 0.080 |
Why?
|
| Decision Trees | 1 | 2006 | 19 | 0.070 |
Why?
|
| Phenylephrine | 4 | 1996 | 36 | 0.070 |
Why?
|
| Fumarates | 1 | 2007 | 11 | 0.070 |
Why?
|
| Respiratory Function Tests | 1 | 2007 | 55 | 0.070 |
Why?
|
| Stress, Psychological | 1 | 1992 | 583 | 0.070 |
Why?
|
| Microfluidic Analytical Techniques | 1 | 2006 | 33 | 0.070 |
Why?
|
| Ventricular Fibrillation | 1 | 2005 | 9 | 0.070 |
Why?
|
| Tachycardia, Ventricular | 1 | 2005 | 12 | 0.070 |
Why?
|
| Liposomes | 1 | 2006 | 118 | 0.070 |
Why?
|
| Radioimmunoassay | 1 | 2005 | 65 | 0.070 |
Why?
|
| Lipid Bilayers | 1 | 2006 | 68 | 0.060 |
Why?
|
| Japan | 1 | 2006 | 305 | 0.060 |
Why?
|
| Fatty Acids, Omega-3 | 1 | 2005 | 36 | 0.060 |
Why?
|
| Confidence Intervals | 2 | 2015 | 149 | 0.060 |
Why?
|
| Thermogenesis | 1 | 2004 | 20 | 0.060 |
Why?
|
| Brain | 1 | 2012 | 1346 | 0.060 |
Why?
|
| Hyperemia | 1 | 2004 | 3 | 0.060 |
Why?
|
| Bacteriolysis | 1 | 2004 | 2 | 0.060 |
Why?
|
| Acrylic Resins | 1 | 2004 | 7 | 0.060 |
Why?
|
| Endotoxins | 2 | 2001 | 18 | 0.060 |
Why?
|
| Statistics as Topic | 2 | 2016 | 117 | 0.060 |
Why?
|
| Ammonia | 1 | 2004 | 17 | 0.060 |
Why?
|
| Chromatography, Gel | 1 | 2004 | 50 | 0.060 |
Why?
|
| Hemochromatosis | 1 | 2004 | 3 | 0.060 |
Why?
|
| Atrial Function, Left | 1 | 2023 | 2 | 0.060 |
Why?
|
| Durapatite | 1 | 2004 | 17 | 0.060 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 3 | 2001 | 623 | 0.060 |
Why?
|
| Urea | 1 | 2004 | 41 | 0.060 |
Why?
|
| Histocompatibility Antigens Class I | 1 | 2004 | 21 | 0.060 |
Why?
|
| Molecular Weight | 1 | 2004 | 167 | 0.060 |
Why?
|
| Age Distribution | 2 | 2015 | 225 | 0.060 |
Why?
|
| Torsion, Mechanical | 2 | 2014 | 3 | 0.060 |
Why?
|
| Electrophoresis, Polyacrylamide Gel | 1 | 2004 | 201 | 0.060 |
Why?
|
| Disease Models, Animal | 2 | 2000 | 1371 | 0.060 |
Why?
|
| Protein Subunits | 1 | 2004 | 87 | 0.060 |
Why?
|
| Intensive Care, Neonatal | 2 | 2000 | 12 | 0.060 |
Why?
|
| Genetic Testing | 1 | 2004 | 75 | 0.060 |
Why?
|
| Cerebrovascular Disorders | 2 | 2015 | 37 | 0.060 |
Why?
|
| Mice | 3 | 2001 | 5913 | 0.050 |
Why?
|
| Verapamil | 1 | 2002 | 7 | 0.050 |
Why?
|
| Enalapril | 1 | 2002 | 7 | 0.050 |
Why?
|
| Insulin Resistance | 1 | 2005 | 184 | 0.050 |
Why?
|
| Anti-Obesity Agents | 1 | 2002 | 10 | 0.050 |
Why?
|
| Lactones | 1 | 2002 | 22 | 0.050 |
Why?
|
| Blood Cell Count | 2 | 2001 | 14 | 0.050 |
Why?
|
| Receptors, Angiotensin | 1 | 2002 | 12 | 0.050 |
Why?
|
| Models, Theoretical | 1 | 2004 | 217 | 0.050 |
Why?
|
| Databases, Factual | 2 | 2015 | 291 | 0.050 |
Why?
|
| Blood Vessels | 1 | 2002 | 34 | 0.050 |
Why?
|
| Veterans | 1 | 2003 | 122 | 0.050 |
Why?
|
| Brazil | 2 | 2012 | 64 | 0.050 |
Why?
|
| Chromatography, High Pressure Liquid | 1 | 2004 | 421 | 0.050 |
Why?
|
| Extracellular Space | 1 | 2001 | 35 | 0.050 |
Why?
|
| Embryonic and Fetal Development | 2 | 1999 | 37 | 0.050 |
Why?
|
| Hematopoiesis | 2 | 1998 | 28 | 0.050 |
Why?
|
| Adrenal Cortex Hormones | 1 | 2002 | 53 | 0.050 |
Why?
|
| Dilatation, Pathologic | 1 | 2021 | 9 | 0.050 |
Why?
|
| Autoantigens | 1 | 2002 | 81 | 0.050 |
Why?
|
| Gout | 1 | 2021 | 13 | 0.050 |
Why?
|
| Cytochrome P-450 CYP2D6 | 1 | 2001 | 17 | 0.050 |
Why?
|
| Filgrastim | 1 | 2000 | 2 | 0.050 |
Why?
|
| Attitude to Health | 1 | 2004 | 325 | 0.050 |
Why?
|
| California | 2 | 2013 | 476 | 0.050 |
Why?
|
| Survival Analysis | 2 | 2016 | 325 | 0.050 |
Why?
|
| Neurotoxins | 1 | 2001 | 57 | 0.050 |
Why?
|
| Platelet Transfusion | 1 | 2000 | 1 | 0.050 |
Why?
|
| Enterocolitis, Necrotizing | 1 | 2000 | 22 | 0.050 |
Why?
|
| Cells | 1 | 2000 | 9 | 0.050 |
Why?
|
| Patient Positioning | 1 | 2020 | 4 | 0.050 |
Why?
|
| Linear Models | 2 | 2012 | 275 | 0.050 |
Why?
|
| Preventive Medicine | 1 | 2000 | 16 | 0.050 |
Why?
|
| Gene Deletion | 1 | 2001 | 166 | 0.050 |
Why?
|
| Erythrocyte Transfusion | 1 | 2000 | 19 | 0.050 |
Why?
|
| Medical History Taking | 1 | 2020 | 33 | 0.050 |
Why?
|
| Sepsis | 1 | 2001 | 80 | 0.050 |
Why?
|
| Drug Stability | 1 | 2000 | 116 | 0.050 |
Why?
|
| Fibroblasts | 1 | 2002 | 272 | 0.050 |
Why?
|
| Lipoproteins | 1 | 2000 | 64 | 0.050 |
Why?
|
| Tissue Distribution | 1 | 2000 | 207 | 0.040 |
Why?
|
| Injections, Intravenous | 1 | 2000 | 62 | 0.040 |
Why?
|
| Digestion | 1 | 1999 | 16 | 0.040 |
Why?
|
| Membrane Proteins | 1 | 2004 | 517 | 0.040 |
Why?
|
| Positron-Emission Tomography | 1 | 2020 | 80 | 0.040 |
Why?
|
| Pre-Eclampsia | 1 | 2000 | 61 | 0.040 |
Why?
|
| Blotting, Northern | 2 | 1996 | 150 | 0.040 |
Why?
|
| Motor Activity | 2 | 2014 | 418 | 0.040 |
Why?
|
| Captopril | 1 | 1999 | 8 | 0.040 |
Why?
|
| Intention to Treat Analysis | 1 | 2019 | 12 | 0.040 |
Why?
|
| Europe | 1 | 2019 | 101 | 0.040 |
Why?
|
| Parkinson Disease | 1 | 2001 | 178 | 0.040 |
Why?
|
| Genotype | 3 | 2011 | 730 | 0.040 |
Why?
|
| Lumbosacral Region | 1 | 1999 | 14 | 0.040 |
Why?
|
| Ischemia | 1 | 1999 | 46 | 0.040 |
Why?
|
| Receptors, Cytokine | 1 | 1999 | 12 | 0.040 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2020 | 214 | 0.040 |
Why?
|
| Thrombocytopenia | 1 | 1999 | 21 | 0.040 |
Why?
|
| Nitrites | 2 | 2013 | 46 | 0.040 |
Why?
|
| Combined Modality Therapy | 2 | 2009 | 148 | 0.040 |
Why?
|
| Mississippi | 1 | 2019 | 122 | 0.040 |
Why?
|
| Microinjections | 2 | 1996 | 57 | 0.040 |
Why?
|
| Epithelial Cells | 1 | 2001 | 384 | 0.040 |
Why?
|
| Nitric Oxide | 1 | 2000 | 316 | 0.040 |
Why?
|
| Mice, Knockout | 1 | 2001 | 933 | 0.040 |
Why?
|
| Teaching Materials | 1 | 1998 | 8 | 0.040 |
Why?
|
| Mitochondria | 1 | 2022 | 487 | 0.040 |
Why?
|
| Tumor Necrosis Factor-alpha | 2 | 2015 | 356 | 0.040 |
Why?
|
| NADH Dehydrogenase | 1 | 2017 | 7 | 0.040 |
Why?
|
| Electron Transport Complex III | 1 | 2017 | 13 | 0.040 |
Why?
|
| Least-Squares Analysis | 2 | 2008 | 43 | 0.040 |
Why?
|
| Fluid Shifts | 1 | 2017 | 2 | 0.040 |
Why?
|
| Agranulocytosis | 1 | 1997 | 1 | 0.040 |
Why?
|
| Neck | 1 | 2017 | 22 | 0.040 |
Why?
|
| Estrogen Replacement Therapy | 1 | 1997 | 44 | 0.040 |
Why?
|
| Family Health | 1 | 1997 | 56 | 0.040 |
Why?
|
| Fatal Outcome | 1 | 1997 | 40 | 0.040 |
Why?
|
| Vasculitis | 1 | 2016 | 4 | 0.040 |
Why?
|
| Oscillometry | 1 | 2016 | 7 | 0.040 |
Why?
|
| Erythroid Precursor Cells | 1 | 1996 | 7 | 0.040 |
Why?
|
| Syndrome | 1 | 1997 | 74 | 0.040 |
Why?
|
| Muscles | 2 | 1994 | 82 | 0.040 |
Why?
|
| Proto-Oncogene Proteins | 1 | 1999 | 239 | 0.040 |
Why?
|
| Umbilical Cord | 1 | 1996 | 14 | 0.040 |
Why?
|
| Blood Flow Velocity | 1 | 2016 | 61 | 0.040 |
Why?
|
| Cells, Cultured | 2 | 2001 | 1518 | 0.040 |
Why?
|
| Neoplasm Proteins | 1 | 1999 | 213 | 0.040 |
Why?
|
| Blood Viscosity | 1 | 1996 | 4 | 0.040 |
Why?
|
| Receptors, Erythropoietin | 1 | 1996 | 7 | 0.040 |
Why?
|
| Oxidative Stress | 2 | 2016 | 938 | 0.040 |
Why?
|
| Antibodies, Monoclonal | 2 | 1996 | 290 | 0.040 |
Why?
|
| Karyotyping | 1 | 1996 | 47 | 0.040 |
Why?
|
| Patient Care Planning | 1 | 2016 | 14 | 0.040 |
Why?
|
| Gene Frequency | 2 | 2011 | 195 | 0.040 |
Why?
|
| Triamterene | 1 | 2016 | 1 | 0.030 |
Why?
|
| Policy Making | 1 | 2016 | 31 | 0.030 |
Why?
|
| Algorithms | 2 | 2009 | 465 | 0.030 |
Why?
|
| Mice, Inbred C57BL | 1 | 2001 | 1609 | 0.030 |
Why?
|
| Fluorometry | 1 | 2016 | 17 | 0.030 |
Why?
|
| Maternal-Fetal Exchange | 1 | 1996 | 29 | 0.030 |
Why?
|
| Primary Prevention | 1 | 2016 | 59 | 0.030 |
Why?
|
| Patient Education as Topic | 1 | 1998 | 215 | 0.030 |
Why?
|
| Nitroprusside | 1 | 1996 | 15 | 0.030 |
Why?
|
| DNA Primers | 1 | 1996 | 286 | 0.030 |
Why?
|
| Actins | 1 | 1996 | 148 | 0.030 |
Why?
|
| Spinal Cord | 1 | 1996 | 94 | 0.030 |
Why?
|
| Herpes Simplex | 1 | 1995 | 16 | 0.030 |
Why?
|
| Streptococcus agalactiae | 1 | 1995 | 10 | 0.030 |
Why?
|
| Pesticides | 1 | 2016 | 52 | 0.030 |
Why?
|
| Cost-Benefit Analysis | 1 | 2016 | 144 | 0.030 |
Why?
|
| Pregnancy Complications | 1 | 1997 | 126 | 0.030 |
Why?
|
| Cytomegalovirus Infections | 1 | 1995 | 23 | 0.030 |
Why?
|
| Streptococcal Infections | 1 | 1995 | 34 | 0.030 |
Why?
|
| Species Specificity | 1 | 1996 | 245 | 0.030 |
Why?
|
| Fasting | 1 | 2015 | 54 | 0.030 |
Why?
|
| Famous Persons | 1 | 1995 | 5 | 0.030 |
Why?
|
| Risk Reduction Behavior | 1 | 2016 | 127 | 0.030 |
Why?
|
| Medicare | 1 | 2017 | 195 | 0.030 |
Why?
|
| Infectious Disease Transmission, Vertical | 1 | 1995 | 72 | 0.030 |
Why?
|
| Disease-Free Survival | 1 | 2015 | 113 | 0.030 |
Why?
|
| Abortion, Induced | 1 | 1996 | 85 | 0.030 |
Why?
|
| Muscle, Smooth, Vascular | 1 | 1996 | 130 | 0.030 |
Why?
|
| History, 20th Century | 1 | 1995 | 117 | 0.030 |
Why?
|
| Dipyridamole | 1 | 2014 | 3 | 0.030 |
Why?
|
| Biological Availability | 1 | 2014 | 88 | 0.030 |
Why?
|
| Social Class | 1 | 2016 | 247 | 0.030 |
Why?
|
| Immunoglobulin G | 1 | 1996 | 237 | 0.030 |
Why?
|
| Myocardial Perfusion Imaging | 1 | 2014 | 6 | 0.030 |
Why?
|
| Injections, Subcutaneous | 1 | 2014 | 33 | 0.030 |
Why?
|
| Macrophages | 1 | 1998 | 439 | 0.030 |
Why?
|
| Nausea | 1 | 2014 | 11 | 0.030 |
Why?
|
| Vomiting | 1 | 2014 | 14 | 0.030 |
Why?
|
| Research Design | 1 | 2016 | 313 | 0.030 |
Why?
|
| Infant | 1 | 1998 | 1046 | 0.030 |
Why?
|
| Apoptosis | 1 | 2002 | 1398 | 0.030 |
Why?
|
| Potassium, Dietary | 1 | 2014 | 1 | 0.030 |
Why?
|
| Physical Education and Training | 1 | 1994 | 28 | 0.030 |
Why?
|
| Supine Position | 1 | 1993 | 7 | 0.030 |
Why?
|
| Water Pollutants, Chemical | 1 | 2016 | 164 | 0.030 |
Why?
|
| Cyclic GMP | 1 | 2013 | 47 | 0.030 |
Why?
|
| Diarrhea | 1 | 2014 | 89 | 0.030 |
Why?
|
| Amine Oxidase (Copper-Containing) | 1 | 2013 | 5 | 0.030 |
Why?
|
| Echocardiography | 1 | 2014 | 144 | 0.030 |
Why?
|
| Collagen | 1 | 2014 | 172 | 0.030 |
Why?
|
| Antigens, CD34 | 1 | 2013 | 19 | 0.030 |
Why?
|
| Cross-Cultural Comparison | 1 | 2013 | 107 | 0.030 |
Why?
|
| Cell Count | 1 | 2013 | 135 | 0.030 |
Why?
|
| Cell Adhesion Molecules | 1 | 2013 | 75 | 0.030 |
Why?
|
| Meta-Analysis as Topic | 1 | 2012 | 30 | 0.030 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2013 | 77 | 0.030 |
Why?
|
| Hypoglycemic Agents | 1 | 2014 | 160 | 0.030 |
Why?
|
| Child, Preschool | 1 | 2016 | 1418 | 0.030 |
Why?
|
| Blood Chemical Analysis | 1 | 2012 | 21 | 0.030 |
Why?
|
| Renal Artery | 1 | 2012 | 7 | 0.030 |
Why?
|
| Health Status Indicators | 1 | 2012 | 75 | 0.030 |
Why?
|
| Furosemide | 1 | 2011 | 10 | 0.030 |
Why?
|
| Executive Function | 1 | 2012 | 49 | 0.030 |
Why?
|
| Dinoprost | 1 | 2011 | 22 | 0.030 |
Why?
|
| Nitroglycerin | 1 | 2011 | 7 | 0.020 |
Why?
|
| Organ Size | 1 | 2011 | 157 | 0.020 |
Why?
|
| Arteriosclerosis | 1 | 1991 | 36 | 0.020 |
Why?
|
| Nervous System | 1 | 1991 | 29 | 0.020 |
Why?
|
| Adaptation, Physiological | 1 | 2012 | 109 | 0.020 |
Why?
|
| Southeastern United States | 1 | 2011 | 49 | 0.020 |
Why?
|
| Emergencies | 1 | 1990 | 24 | 0.020 |
Why?
|
| Genetic Markers | 1 | 2011 | 142 | 0.020 |
Why?
|
| Environment | 1 | 2011 | 138 | 0.020 |
Why?
|
| Observer Variation | 1 | 2009 | 52 | 0.020 |
Why?
|
| Adrenergic alpha-Antagonists | 1 | 1989 | 31 | 0.020 |
Why?
|
| Brain Ischemia | 1 | 1991 | 184 | 0.020 |
Why?
|
| Diet, Reducing | 1 | 2009 | 24 | 0.020 |
Why?
|
| Biopsy | 2 | 2000 | 164 | 0.020 |
Why?
|
| Educational Status | 1 | 2010 | 313 | 0.020 |
Why?
|
| Inflammation | 1 | 2013 | 618 | 0.020 |
Why?
|
| Echocardiography, Doppler | 1 | 2008 | 37 | 0.020 |
Why?
|
| Counseling | 1 | 2009 | 116 | 0.020 |
Why?
|
| Smoking Cessation | 1 | 2014 | 517 | 0.020 |
Why?
|
| Software | 1 | 2009 | 217 | 0.020 |
Why?
|
| Imaging, Three-Dimensional | 1 | 2008 | 84 | 0.020 |
Why?
|
| Medication Errors | 1 | 2007 | 6 | 0.020 |
Why?
|
| Treatment Refusal | 1 | 2007 | 20 | 0.020 |
Why?
|
| Electrophysiology | 2 | 2001 | 136 | 0.020 |
Why?
|
| Gene Expression | 2 | 2001 | 674 | 0.020 |
Why?
|
| Avidin | 1 | 2006 | 6 | 0.020 |
Why?
|
| Biotin | 1 | 2006 | 24 | 0.020 |
Why?
|
| Drug Synergism | 1 | 2007 | 177 | 0.020 |
Why?
|
| Silicon Dioxide | 1 | 2006 | 34 | 0.020 |
Why?
|
| Amides | 1 | 2007 | 68 | 0.020 |
Why?
|
| Polyethylene Glycols | 1 | 2006 | 84 | 0.020 |
Why?
|
| Microscopy, Confocal | 1 | 2006 | 218 | 0.020 |
Why?
|
| Erythrocyte Membrane | 1 | 2005 | 20 | 0.020 |
Why?
|
| Waist-Hip Ratio | 1 | 2005 | 34 | 0.020 |
Why?
|
| Exercise Test | 1 | 2005 | 67 | 0.020 |
Why?
|
| Cholesterol, HDL | 1 | 2005 | 97 | 0.020 |
Why?
|
| Signal Transduction | 1 | 2013 | 1908 | 0.020 |
Why?
|
| Angiography | 1 | 2003 | 15 | 0.010 |
Why?
|
| Electrocardiography, Ambulatory | 1 | 2002 | 12 | 0.010 |
Why?
|
| Insulin | 1 | 2005 | 236 | 0.010 |
Why?
|
| Blood Glucose | 1 | 2005 | 353 | 0.010 |
Why?
|
| Rats, Sprague-Dawley | 2 | 2000 | 1618 | 0.010 |
Why?
|
| Referral and Consultation | 1 | 2003 | 117 | 0.010 |
Why?
|
| Statistics, Nonparametric | 1 | 2002 | 108 | 0.010 |
Why?
|
| Delayed-Action Preparations | 1 | 2002 | 60 | 0.010 |
Why?
|
| Interviews as Topic | 1 | 2004 | 381 | 0.010 |
Why?
|
| Hydrolases | 1 | 2002 | 15 | 0.010 |
Why?
|
| Glucuronidase | 1 | 2002 | 15 | 0.010 |
Why?
|
| Okadaic Acid | 1 | 2002 | 15 | 0.010 |
Why?
|
| Acid Phosphatase | 1 | 2002 | 21 | 0.010 |
Why?
|
| beta-Galactosidase | 1 | 2002 | 35 | 0.010 |
Why?
|
| False Positive Reactions | 1 | 2001 | 26 | 0.010 |
Why?
|
| Ceramides | 1 | 2002 | 42 | 0.010 |
Why?
|
| Energy Intake | 1 | 2002 | 170 | 0.010 |
Why?
|
| HIV Infections | 1 | 1995 | 2303 | 0.010 |
Why?
|
| Macrophages, Alveolar | 1 | 2001 | 34 | 0.010 |
Why?
|
| Lysosomes | 1 | 2002 | 91 | 0.010 |
Why?
|
| Dexamethasone | 1 | 2001 | 45 | 0.010 |
Why?
|
| Homozygote | 1 | 2001 | 77 | 0.010 |
Why?
|
| Patch-Clamp Techniques | 1 | 2001 | 223 | 0.010 |
Why?
|
| DNA Mutational Analysis | 1 | 2001 | 93 | 0.010 |
Why?
|
| Glucocorticoids | 1 | 2001 | 86 | 0.010 |
Why?
|
| Lymphocytes | 1 | 2001 | 118 | 0.010 |
Why?
|
| Lipids | 1 | 2002 | 235 | 0.010 |
Why?
|
| NG-Nitroarginine Methyl Ester | 1 | 2000 | 36 | 0.010 |
Why?
|
| Nitrates | 1 | 2000 | 40 | 0.010 |
Why?
|
| Nerve Degeneration | 1 | 2001 | 107 | 0.010 |
Why?
|
| Trophoblasts | 1 | 2000 | 24 | 0.010 |
Why?
|
| Endothelium | 1 | 2000 | 31 | 0.010 |
Why?
|
| Epithelium | 1 | 2000 | 79 | 0.010 |
Why?
|
| Oxygen | 1 | 2001 | 207 | 0.010 |
Why?
|
| Alleles | 1 | 2001 | 321 | 0.010 |
Why?
|
| Renal Veins | 1 | 1999 | 2 | 0.010 |
Why?
|
| Fetal Diseases | 1 | 1999 | 7 | 0.010 |
Why?
|
| Venous Thrombosis | 1 | 1999 | 28 | 0.010 |
Why?
|
| Necrosis | 1 | 1999 | 49 | 0.010 |
Why?
|
| Receptors, Thrombopoietin | 1 | 1999 | 1 | 0.010 |
Why?
|
| Platelet Count | 1 | 1999 | 13 | 0.010 |
Why?
|
| Erythrocyte Count | 1 | 1998 | 11 | 0.010 |
Why?
|
| Environmental Exposure | 1 | 2001 | 216 | 0.010 |
Why?
|
| Triplets | 1 | 1998 | 4 | 0.010 |
Why?
|
| Twins | 1 | 1998 | 17 | 0.010 |
Why?
|
| Receptor, Macrophage Colony-Stimulating Factor | 1 | 1998 | 3 | 0.010 |
Why?
|
| Macrophage Colony-Stimulating Factor | 1 | 1998 | 10 | 0.010 |
Why?
|
| Peroxidase | 1 | 1998 | 49 | 0.010 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2001 | 628 | 0.010 |
Why?
|
| Lung | 1 | 2000 | 446 | 0.010 |
Why?
|
| Anti-Bacterial Agents | 1 | 2000 | 352 | 0.010 |
Why?
|
| RNA-Directed DNA Polymerase | 1 | 1996 | 18 | 0.010 |
Why?
|
| Flow Cytometry | 1 | 1998 | 399 | 0.010 |
Why?
|
| Pregnancy Trimester, Second | 1 | 1996 | 16 | 0.010 |
Why?
|
| Bone and Bones | 1 | 1996 | 86 | 0.010 |
Why?
|
| Transcription, Genetic | 1 | 1996 | 578 | 0.010 |
Why?
|
| Electrodiagnosis | 1 | 1992 | 2 | 0.010 |
Why?
|
| Microelectrodes | 1 | 1992 | 23 | 0.010 |
Why?
|
| Medulla Oblongata | 1 | 1992 | 40 | 0.010 |
Why?
|
| Exercise Therapy | 1 | 1992 | 69 | 0.010 |
Why?
|